ATA3271 / Atara - LARVOL DELTA

ATA3271: An Armored, Next-Generation Off-The-Shelf, Allogeneic, Mesothelin-CAR T Cell Therapy for Solid Tumors (SITC 2021) - P1, P3 | "Memory marker expression impact on ATA3271 potency, both in vitro and in vivo, will be presented. Conclusions Overall, these in vitro and in vivo data show potent anti-tumor activity without evidence of toxicity, suggesting that ATA3271 may be a promising approach for the treatment of MSLN-positive cancers that warrants further clinical investigation."

CAR T-Cell Therapy • IO biomarker • Lung Cancer • Malignant Pleural Mesothelioma • Mesothelioma • Oncology • Solid Tumor • CCR7 • CD19 • GZMB • IL2 • MSLN • PD-L1 • TNFA

[VIRTUAL] ATA3271: An Armored, Next-Generation Off-The-Shelf, Allogeneic, Mesothelin-CAR T Cell Therapy for Solid Tumors (SITC 2020) - P3 | "Additionally, ATA3271 retains endogenous EBV TCR function and reduced allotoxicity in the context of HLA mismatched targets. Conclusions Overall, ATA3271 shows potent anti-tumor activity without evidence of allotoxicity, both in vitro and in vivo, suggesting that allogeneic MSLN-CAR-engineered EBV T cells are a promising approach for the treatment of MSLN-positive cancers and warrant further clinical investigation."

CAR T-Cell Therapy • IO Biomarker • Gastrointestinal Cancer • Lung Cancer • Malignant Pleural Mesothelioma • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CD19 • MSLN • PD-L1

[VIRTUAL] ATA3271: An Armored, Next-Generation Off-The-Shelf, Allogeneic, Mesothelin-CAR T Cell Therapy for Solid Tumors (SITC 2020) - P3 | "Additionally, ATA3271 retains endogenous EBV TCR function and reduced allotoxicity in the context of HLA mismatched targets. Conclusions Overall, ATA3271 shows potent anti-tumor activity without evidence of allotoxicity, both in vitro and in vivo, suggesting that allogeneic MSLN-CAR-engineered EBV T cells are a promising approach for the treatment of MSLN-positive cancers and warrant further clinical investigation."

CAR T-Cell Therapy • IO Biomarker • Gastrointestinal Cancer • Lung Cancer • Malignant Pleural Mesothelioma • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CD19 • MSLN • PD-L1

BAY1688/ATA3271: An Armored, Next-Generation, Off-the-Shelf Mesothelin-CAR T Cell Therapy for Solid Tumors (ASGCT 2022) - P1, P3 | "Conclusions These studies reveal potent anti-tumor activity, both in vitro and in vivo, of BAY1688/ATA3271 allogeneic CAR-T cells generated using an original and an optimized manufacturing process. Overall, BAY1688/ATA3271 may be a promising approach for the treatment of MSLN-positive malignancies, and this data warrants further development of this program towards clinical trials."

CAR T-Cell Therapy • IO biomarker • Lung Cancer • Malignant Pleural Mesothelioma • Mesothelioma • Oncology • Solid Tumor • Transplantation • CD19 • GZMB • IL2 • MSLN • PD-L1 • TNFA

Atara Biotherapeutics Provides Update on Strategic Collaboration with Bayer (Businesswire) - "Atara Biotherapeutics...announced that it received notification of Bayer’s intention to end the exclusive worldwide licensing agreement for next-generation mesothelin-directed CAR T-cell therapies. The collaboration included the funding and development of ATA3271, an armored allogeneic T-cell immunotherapy, and an autologous version, ATA2271, for high mesothelin-expressing tumors such as malignant pleural mesothelioma and non-small-cell lung cancer....Upon termination of the agreement in September 2022, the rights and licenses granted by Atara to Bayer under the collaboration will be returned to Atara....'We will postpone the anticipated IND filing for ATA3271 beyond the fourth quarter of 2022'."

IND • Licensing / partnership • Lung Cancer • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer

Atara Biotherapeutics Announces the Completion of the Acquisition of Its Cell Therapy Manufacturing Facility & Commencement of Long-Term Strategic Partnership with Fujifilm (Yahoo Finance) - "Atara Biotherapeutics...announced FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation (Fujifilm), has completed the acquisition of Atara’s cell therapy manufacturing facility in Thousand Oaks, California for USD 100 million upfront and the commencement of a long-term strategic supply agreement....With the closing of the transaction, FUJIFILM Diosynth Biotechnologies will provide Atara with access to the flexible capacity and specific capability needed to manufacture clinical and commercial-stage allogeneic cell therapies for its maturing and promising pipeline, including tabelecleucel (tab-cel®), ATA188 for multiple sclerosis, and allogeneic CAR T therapies, ATA3271 and ATA3219."

Financing • Licensing / partnership • Hematological Malignancies • Oncology

Atara Biotherapeutics to Present Recent Progress and Key Upcoming Catalysts at the 40th Annual J.P. Morgan Healthcare Conference (Businesswire) - "Atara is continuing to make progress on IND-enabling studies for ATA3271, an off-the-shelf, allogeneic CAR-T therapy targeting mesothelin using next-generation PD-1 dominant negative receptor (DNR) and 1XX CAR co-stimulatory signaling domain technologies for patients with advanced mesothelioma, and expects a filing in Q4 2022; ATA3219 (B-cell Malignancies): Atara expects to submit an IND for B-cell malignancies in Q4 2022."

IND • Hematological Malignancies • Oncology • Solid Tumor

Atara Biotherapeutics Announces Second Quarter 2021 Financial Results and Operational Progress (Businesswire) - "Atara is continuing to make progress on IND-enabling studies for ATA3271...and expects an IND filing in H2 2022....The Company plans to present preclinical data for ATA3271 at an appropriate forum in Q4 2021....Atara expects to submit an IND for ATA3219, an off-the-shelf, allogeneic CD19 CAR T immunotherapy targeting B-cell malignancies, as a potential best-in-class therapy without the need for T-cell receptor (TCR) gene editing...in Q1 2022....Based on the outcome of the recent and anticipated interactions with the FDA, Atara expects to complete the BLA submission for tab-cel® in Q1 2022."

IND • Preclinical • Hematological Malignancies • Oncology • Solid Tumor

Atara Biotherapeutics Announces Third Quarter 2021 Financial Results and Operational Progress (Businesswire) - "The first presentation of preclinical, clinical, and translational data from the lowest dose cohorts of the open-label, single-arm Phase 1 clinical study of ATA2271, an autologous CAR-T therapy targeting mesothelin, designed to improve efficacy, persistence, and durability of response for patients with advanced mesothelioma, will take place during a Mini Oral session at the ESMO Immuno-Oncology Congress on December 9, 2021 (presentation #46MO. Preclinical data for ATA3271 will be presented at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting, taking place November 10-14, 2021 (poster #136)."

Preclinical • Oncology

Bayer and Atara Biotherapeutics Enter Strategic Collaboration for Mesothelin-Targeted CAR T-cell Therapies for Solid Tumors (Businesswire) - "Bayer and Atara Biotherapeutics...announced an exclusive worldwide license agreement and research, development and manufacturing collaboration for mesothelin-directed CAR T-cell therapies for the treatment of solid tumors. The agreement includes the development candidate ATA3271, an armored allogeneic T-cell immunotherapy, and an autologous version, ATA2271, for high mesothelin-expressing tumors such as malignant pleural mesothelioma and non-small-cell lung cancer...Under the terms of the agreement, Atara will lead IND (Investigational New Drug)-enabling studies and process development for ATA3271 while Bayer will be responsible for submitting the IND and subsequent clinical development and commercialization."

Licensing / partnership • Lung Cancer • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Bayer Enters CAR-T Space With Atara Pact (Scripintelligence) - "Pays $60m Upfront..."

Licensing / partnership • Lung Cancer • Non Small Cell Lung Cancer • Oncology

Atara Biotherapeutics Presents New Preclinical Data on ATA3271, a Next-Generation Allogeneic Mesothelin-Targeted CAR T to Treat Solid Tumors, at the 35th Society for Immunotherapy of Cancer Annual Meeting (SITC 2020) (Businesswire) - “Atara Biotherapeutics, Inc…announced the presentation of the first preclinical evaluation of ATA3271, a next-generation, off-the-shelf, allogeneic EBV CAR T-cell therapy targeting mesothelin designed for the treatment of solid tumors…These data support the design of ATA3271, which expresses a dominant negative version of PD-1 receptor, to maintain function in the presence of suppressive checkpoint ligands commonly associated with solid tumor microenvironments. In addition, results further support the combined functional design of ATA3271’s 1XX costimulatory domain technology in maintaining memory phenotype while limiting cell exhaustion in the context of repeated tumor cell challenges.”

Preclinical • Oncology

Atara Biotherapeutics Announces Third Quarter 2020 Financial Results and Operational Progress (Businesswire) - “ATA2271/ATA3271 (Solid Tumors Over-Expressing Mesothelin): The open-label, single-arm Phase 1 clinical study of ATA2271…MSK is on track to enroll the first patient in the Phase 1 study in Q4 2020; In new preclinical data, ATA3271 demonstrates potent anti-tumor activity, functional persistence and significant survival benefit with no evidence of allocytotoxicity in vivo, suggesting that allogeneic MSLN-CAR-engineered EBV T cells are a promising approach for the treatment of MSLN-positive cancers. These data will be presented at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting November 11-14, 2020.”

Enrollment status • Preclinical • Mesothelioma • Oncology